ZykadiaCyramzaFruzaqlaFruquintinibImfinzidurvalumabramucirumabBrigatinibceritinib
…), atezolizumab (Tecentriq), osimertinib (Tagrisso), ceritinib (Zykadia) and nintedanib (Vargatef). EMA labels for all products include…
5articles mentioning drugs
18drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: ramucirumab ×
ramucirumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning ramucirumab
5 articles · page 1 of 1docetaxelpembrolizumabtislelizumabsitravatinib
…patient in sitravatinib+tislelizumab arm; 13 (6.8%) patients in docetaxel arm) (figure 1). One patient randomised to sitravatinib+tisleli…
sotorasibramucirumabdocetaxelARPIscancerCommon Sense Oncology initiativeFDANational Comprehensive Cancer Networkhigh-risk hormone-sensitive prostate cancerLMICs+3 more
… rather than to high-cost agents with marginal efficacy such as sotorasib or ramucirumab.Third, it is unacceptable to use inferior contro…
HCB101HCB101-basedHCB101-201nab-paclitaxelramucirumabpaclitaxeltoripalimabgastric cancerhead and neck squamous cell carcinomatriple-negative breast cancer+1 more
… plus ramucirumab and paclitaxel); and b) first-line (1L) TNBC (HCB101 plus toripalimab and nab-paclitaxel). Primary endpoints were sa…
paclitaxeltrastuzumabramucirumabevorpaceptevoevo-TRPevo-basedTRPHER2-overexpressing gastric/gastroesophageal cancer (GC)
…d PFS in combination with trastuzumab (T), ramucirumab (R), and paclitaxel (P) in advanced, previously treated HER2+ gastric/gastroesophag…